Lantern Pharma launches withZeta.ai commercial platform for cancer research
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSi
April 14, 2026 8:31 AM EDTPlatform Now Available with Introductory, Academic, & Commercial Subscription Tiers Live Debut at Nasdaq MarketSite, New York City April 16, 2026, 12:002:00 PM Eastern Public Demonstrations at AACR 2026, San Diego Booth 5054, April 1722
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (Nasdaq: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai the worlds first and most... More
